QUANTUM GENOMICS SAS-REGR (ALQGC.PA)

Company Profile

Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.

Company Info

QUANTUM GENOMICS SAS-REGR

33 rue Marbeuf

Paris ILE-DE-FRANCE

P: 33185347770

Employees: 3

Website: https://quantum-genomics.com/